WEKO3
アイテム
{"_buckets": {"deposit": "0e8fea0c-3eaf-45f9-83f8-507b56619b94"}, "_deposit": {"id": "2152", "owners": [], "pid": {"revision_id": 0, "type": "depid", "value": "2152"}, "status": "published"}, "_oai": {"id": "oai:niigata-u.repo.nii.ac.jp:00002152", "sets": ["454", "484"]}, "item_5_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2004-07", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "7", "bibliographicPageEnd": "698", "bibliographicPageStart": "691", "bibliographicVolumeNumber": "28", "bibliographic_titles": [{"bibliographic_title": "Leukemia Research"}, {"bibliographic_title": "Leukemia Research", "bibliographic_titleLang": "en"}]}]}, "item_5_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Like CD19 or CD56, CD22 in non-lymphoid leukemia has been considered an aberrantly expressed antigen. CD22 had been believed to be restricted to B lymphoid, however, it was also found to be expressed in human basophils. Mature basophils are unique granulocytes expressing CD13, CD22 and CD25. To estimate whether the expression of CD22 in non-lymphoid leukemia is aberrant or related to basophilic character, we analyzed 108 patients with primary and secondary leukemia. Among non-lymphoid leukemias, surface CD22 expression was more frequently observed in peroxidase-negative AML and secondary leukemia, and was usually observed simultaneously with CD13 and CD25. Samples obtained from 17 cases were further analyzed, and all the FcεR1-positive cases were observed in peroxidase-negative AML and secondary non-lymphoid leukemia, and mostly expressed CD13, CD22 and CD25. Therefore, surface CD22 expression in non-lymphoid leukemia was thought to relate to basophilic phenotype in some cases. Like CD22, some of the so-called aberrantly expressed antigens may not actually be aberrant, but are expressed in a stage of differentiation and maturation of progenitors. Moreover, CD22 may be one of target molecules for treatment of CD22-positive, poorly prognostic leukemia.", "subitem_description_type": "Abstract"}]}, "item_5_full_name_3": {"attribute_name": "著者別名", "attribute_value_mlt": [{"nameIdentifiers": [{"nameIdentifier": "7241", "nameIdentifierScheme": "WEKO"}], "names": [{"name": "鳥羽, 健"}]}]}, "item_5_publisher_7": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "Elsevier"}]}, "item_5_relation_14": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_type_id": {"subitem_relation_type_id_text": "info:doi/10.1016/j.leukres.2003.10.034", "subitem_relation_type_select": "DOI"}}]}, "item_5_rights_15": {"attribute_name": "権利", "attribute_value_mlt": [{"subitem_rights": "Elsevier Ltd"}]}, "item_5_select_19": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_select_item": "author"}]}, "item_5_source_id_11": {"attribute_name": "書誌レコードID", "attribute_value_mlt": [{"subitem_source_identifier": "AA00716755", "subitem_source_identifier_type": "NCID"}]}, "item_5_source_id_9": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "01452126", "subitem_source_identifier_type": "ISSN"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Sato, Naoko"}], "nameIdentifiers": [{"nameIdentifier": "7233", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kishi, Kenji"}], "nameIdentifiers": [{"nameIdentifier": "7234", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Toba, Ken"}], "nameIdentifiers": [{"nameIdentifier": "7235", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Watanabe, Kenichi"}], "nameIdentifiers": [{"nameIdentifier": "7236", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Itoh, Hiromi"}], "nameIdentifiers": [{"nameIdentifier": "7237", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Narita, Miwako"}], "nameIdentifiers": [{"nameIdentifier": "7238", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Takahashi, Masuhiro"}], "nameIdentifiers": [{"nameIdentifier": "7239", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Aizawa, Yoshifusa"}], "nameIdentifiers": [{"nameIdentifier": "7240", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2019-07-29"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "24_0011.pdf", "filesize": [{"value": "1.5 MB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 1500000.0, "url": {"label": "24_0011.pdf", "url": "https://niigata-u.repo.nii.ac.jp/record/2152/files/24_0011.pdf"}, "version_id": "d540b4cd-e0ca-480e-b4e5-13e3ec787285"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "CD22", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Leu14", "subitem_subject_scheme": "Other"}, {"subitem_subject": "FcεR1", "subitem_subject_scheme": "Other"}, {"subitem_subject": "acute non-lymphocytic leukemia", "subitem_subject_scheme": "Other"}, {"subitem_subject": "basophils", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Simultaneous expression of CD13, CD22 and CD25 is related to the expression of FcεR1 in non-lymphoid leukemia", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Simultaneous expression of CD13, CD22 and CD25 is related to the expression of FcεR1 in non-lymphoid leukemia"}, {"subitem_title": "Simultaneous expression of CD13, CD22 and CD25 is related to the expression of FcεR1 in non-lymphoid leukemia", "subitem_title_language": "en"}]}, "item_type_id": "5", "owner": "1", "path": ["454", "484"], "permalink_uri": "http://hdl.handle.net/10191/1178", "pubdate": {"attribute_name": "公開日", "attribute_value": "2007-04-23"}, "publish_date": "2007-04-23", "publish_status": "0", "recid": "2152", "relation": {}, "relation_version_is_last": true, "title": ["Simultaneous expression of CD13, CD22 and CD25 is related to the expression of FcεR1 in non-lymphoid leukemia"], "weko_shared_id": null}
Simultaneous expression of CD13, CD22 and CD25 is related to the expression of FcεR1 in non-lymphoid leukemia
http://hdl.handle.net/10191/1178
http://hdl.handle.net/10191/117880e7d95c-6036-4d84-ad51-4b97ff07ff80
名前 / ファイル | ライセンス | アクション |
---|---|---|
24_0011.pdf (1.5 MB)
|
|
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2007-04-23 | |||||
タイトル | ||||||
タイトル | Simultaneous expression of CD13, CD22 and CD25 is related to the expression of FcεR1 in non-lymphoid leukemia | |||||
タイトル | ||||||
言語 | en | |||||
タイトル | Simultaneous expression of CD13, CD22 and CD25 is related to the expression of FcεR1 in non-lymphoid leukemia | |||||
言語 | ||||||
言語 | eng | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | CD22 | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Leu14 | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | FcεR1 | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | acute non-lymphocytic leukemia | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | basophils | |||||
資源タイプ | ||||||
資源 | http://purl.org/coar/resource_type/c_6501 | |||||
タイプ | journal article | |||||
著者 |
Sato, Naoko
× Sato, Naoko× Kishi, Kenji× Toba, Ken× Watanabe, Kenichi× Itoh, Hiromi× Narita, Miwako× Takahashi, Masuhiro× Aizawa, Yoshifusa |
|||||
著者別名 | ||||||
識別子 | 7241 | |||||
識別子Scheme | WEKO | |||||
姓名 | 鳥羽, 健 | |||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Like CD19 or CD56, CD22 in non-lymphoid leukemia has been considered an aberrantly expressed antigen. CD22 had been believed to be restricted to B lymphoid, however, it was also found to be expressed in human basophils. Mature basophils are unique granulocytes expressing CD13, CD22 and CD25. To estimate whether the expression of CD22 in non-lymphoid leukemia is aberrant or related to basophilic character, we analyzed 108 patients with primary and secondary leukemia. Among non-lymphoid leukemias, surface CD22 expression was more frequently observed in peroxidase-negative AML and secondary leukemia, and was usually observed simultaneously with CD13 and CD25. Samples obtained from 17 cases were further analyzed, and all the FcεR1-positive cases were observed in peroxidase-negative AML and secondary non-lymphoid leukemia, and mostly expressed CD13, CD22 and CD25. Therefore, surface CD22 expression in non-lymphoid leukemia was thought to relate to basophilic phenotype in some cases. Like CD22, some of the so-called aberrantly expressed antigens may not actually be aberrant, but are expressed in a stage of differentiation and maturation of progenitors. Moreover, CD22 may be one of target molecules for treatment of CD22-positive, poorly prognostic leukemia. | |||||
書誌情報 |
Leukemia Research en : Leukemia Research 巻 28, 号 7, p. 691-698, 発行日 2004-07 |
|||||
出版者 | ||||||
出版者 | Elsevier | |||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 01452126 | |||||
書誌レコードID | ||||||
収録物識別子タイプ | NCID | |||||
収録物識別子 | AA00716755 | |||||
DOI | ||||||
識別子タイプ | DOI | |||||
関連識別子 | info:doi/10.1016/j.leukres.2003.10.034 | |||||
権利 | ||||||
権利情報 | Elsevier Ltd | |||||
著者版フラグ | ||||||
値 | author |